What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call

What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call

Ionis Pharmaceuticals (NASDAQ:IONS) lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive cash flow back by a year. The biotechnology company now expects approximately $50 million in full-yea

Ionis reports third quarter 2026 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Nov 9, 2026-

Arrowhead Stock Tumbles 15% on Same Day Rival Ionis Cuts Tryngolza Forecast in Triglyceride Drug Market

Arrowhead Pharmaceuticals shares dropped 15.4% after rival Ionis sharply reduced its Tryngolza sales forecast, raising concerns about demand and the pace of growth in the severe hypertriglyceridaemia market.

Why Ionis (IONS) Stock Crashed Monday Even After Beating Earnings

TLDR Ionis (IONS) stock fell about 28% to $28.15 on Monday, its worst day since May 2016. The company cut its 2026 Tryngolza sales outlook to about $50 million from $100 million to $110 million. Third-quarter revenue hit $243 million, well above the $178.2 million analysts expected. Full-year revenue guidance of $875 million to $900 [...]

Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.